Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression / Vanina Popova en The American Journal of Psychiatry, Año 2019 - Vol. 176 - No. 6 (Junio)

Público ISBD [artículo]  inThe American Journal of Psychiatry > Año 2019 - Vol. 176 - No. 6 (Junio) . - pp. 428-438 Título : Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : A randomized double-blind active-controlled study Tipo de documento: texto impreso Autores: Vanina Popova, Autor ; Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor Fecha de publicación: 2019 Artículo en la página: pp. 428-438 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Esketamina, SKetamine, Ketamina, Depresión resistente al tratamiento, Trastorno depresivo mayor Resumen: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray. Link: ./index.php?lvl=notice_display&id=20716 [artículo] Efficacy and safety of flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression : A randomized double-blind active-controlled study [texto impreso] / Vanina Popova, Autor ; Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor . - 2019 . - pp. 428-438. Idioma : Inglés (eng) Idioma original : Inglés (eng) in The American Journal of Psychiatry > Año 2019 - Vol. 176 - No. 6 (Junio) . - pp. 428-438 Palabras clave: Esketamina, SKetamine, Ketamina, Depresión resistente al tratamiento, Trastorno depresivo mayor Resumen: About one-third of patients with depression fail to achieve remission despite treatment with multiple antidepressants. This study compared the efficacy and safety of switching patients with treatment-resistant depression from an ineffective antidepressant to flexibly dosed esketamine nasal spray plus a newly initiated antidepressant or to a newly initiated antidepressant (active comparator) plus placebo nasal spray. Link: ./index.php?lvl=notice_display&id=20716

The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study / Ella J. Daly en Journal of Clinical Psychopharmacology, Año 2011 - Vol. 31 - No. 1 (Febrero)

Público ISBD [artículo]  inJournal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 31-38 Título : The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study Tipo de documento: texto impreso Autores: Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor ; Maurizio Fava, Autor Fecha de publicación: 2022 Artículo en la página: pp. 31-38 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Trastorno depresivo mayor, Eventos adversos, Remisión Resumen: Little is known about the association between antidepressant treatment-emergent adverse events and symptom nonremission in major depressive disorder. The objective of the current analysis was to determine whether particular baseline symptoms or treatment-emergent symptoms (adverse events) during the first 2 weeks are associated with nonremission after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). Link: ./index.php?lvl=notice_display&id=29405 [artículo] The relationship between adverse events during selective serotonin reuptake inhibitor treatment for major depressive disorder and nonremission in the suicide assessment methodology study [texto impreso] / Ella J. Daly, Autor ; Madhukar H. Trivedi, Autor ; Maurizio Fava, Autor . - 2022 . - pp. 31-38. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Journal of Clinical Psychopharmacology > Año 2011 - Vol. 31 - No. 1 (Febrero) . - pp. 31-38 Palabras clave: Trastorno depresivo mayor, Eventos adversos, Remisión Resumen: Little is known about the association between antidepressant treatment-emergent adverse events and symptom nonremission in major depressive disorder. The objective of the current analysis was to determine whether particular baseline symptoms or treatment-emergent symptoms (adverse events) during the first 2 weeks are associated with nonremission after 8 weeks of treatment with a selective serotonin reuptake inhibitor (SSRI). Link: ./index.php?lvl=notice_display&id=29405

Treatment strategies to improve and sustain remission in major depressive disorder / Madhukar H. Trivedi en Dialogues in Clinical Neuroscience, Año 2008 Vol.10 - No.4 (Diciembre)

Público ISBD [artículo]  inDialogues in Clinical Neuroscience > Año 2008 Vol.10 - No.4 (Diciembre) . - pp. 377–384 Título : Treatment strategies to improve and sustain remission in major depressive disorder Tipo de documento: texto impreso Autores: Madhukar H. Trivedi, Autor ; Ella J. Daly, Autor Fecha de publicación: 2022 Artículo en la página: pp. 377–384 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Remisión, Depresión resistente al tratamiento, Función Resumen: Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). Link: ./index.php?lvl=notice_display&id=28727 [artículo] Treatment strategies to improve and sustain remission in major depressive disorder [texto impreso] / Madhukar H. Trivedi, Autor ; Ella J. Daly, Autor . - 2022 . - pp. 377–384. Idioma : Inglés (eng) Idioma original : Inglés (eng) in Dialogues in Clinical Neuroscience > Año 2008 Vol.10 - No.4 (Diciembre) . - pp. 377–384 Palabras clave: Remisión, Depresión resistente al tratamiento, Función Resumen: Major depressive disorder (MDD) is an often chronic, recurrent illness affecting large numbers of the general population. In recent years, the goal of treatment for MDD has moved from mere symptomatic response to that of full remission (ie, minimal/no residual symptoms). Link: ./index.php?lvl=notice_display&id=28727

---

1 (1 - 3 / 3)